New Pre-Surgery combo aims to wipe out colon cancer cells
NCT ID NCT06124378
Summary
This study is testing a new treatment approach for people with a common type of locally advanced colon cancer. Before having standard surgery, participants receive a combination of an immunotherapy drug (tislelizumab) and two chemotherapy drugs (oxaliplatin and capecitabine). The main goal is to see if this pre-surgery treatment can completely eliminate all cancer cells in the removed tumor, which may lead to better long-term survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.